Acurx Pharmaceuticals (NASDAQ:ACXP) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) posted its earnings results on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03), FiscalAI reports.

Here are the key takeaways from Acurx Pharmaceuticals’ conference call:

• Acurx said it is starting an rCDI clinical program for ibezapolstat, beginning with a 20-patient open-label pilot, and management believes the drug could ultimately become a single-agent approach for treating acute C. difficile infection and preventing recurrence.
• The company highlighted encouraging prior phase II data, including a 96% cure rate and no recurrences among cured patients, and said the new microbiome-sparing profile may support ibezapolstat’s differentiation versus existing therapies.
• Management pointed to the FDA’s recent final guidance suggesting that, in some cases, one adequate and well-controlled trial with confirmatory evidence may be sufficient for C. difficile registration, which could potentially simplify Acurx’s acute CDI development path.
• Acurx also said the April financing, together with its equity line of credit, provides the cash resources to fund the exploratory rCDI trial, and the company ended Q1 2026 with $9.3 million in cash.
• First-quarter results showed a net loss of $1.7 million versus $2.1 million a year ago, with lower R&D and G&A expenses year over year. The company said it expects the rCDI trial to start up now and is targeting a first patient in August.

Acurx Pharmaceuticals Stock Down 2.2%

NASDAQ ACXP traded down $0.05 during trading on Wednesday, hitting $2.01. The stock had a trading volume of 36,733 shares, compared to its average volume of 2,152,728. The company has a market capitalization of $5.73 million, a PE ratio of -0.50 and a beta of -2.09. The firm has a 50 day moving average price of $3.07 and a 200 day moving average price of $3.27. Acurx Pharmaceuticals has a twelve month low of $1.33 and a twelve month high of $21.00.

Institutional Investors Weigh In On Acurx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new position in shares of Acurx Pharmaceuticals in the fourth quarter worth $31,000. Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals in the second quarter valued at $551,000. Millennium Management LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter worth $103,000. Finally, Jane Street Group LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter worth $27,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ACXP has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Acurx Pharmaceuticals to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).